217 related articles for article (PubMed ID: 28980300)
1. CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention.
Cicek G; Yıldırım E
Kardiol Pol; 2018; 76(1):91-98. PubMed ID: 28980300
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of ATRIA risk score for contrast-induced nephropathy after percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Aksoy F; Bagcı A
Rev Assoc Med Bras (1992); 2019 Nov; 65(11):1384-1390. PubMed ID: 31800901
[TBL] [Abstract][Full Text] [Related]
3. New CHA
Zhang QY; Ma SM; Sun JY
BMC Cardiovasc Disord; 2020 Jul; 20(1):346. PubMed ID: 32711475
[TBL] [Abstract][Full Text] [Related]
4. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
[TBL] [Abstract][Full Text] [Related]
5. CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome.
Chaudhary AK; Pathak V; Kunal S; Shukla S; Pathak P
Indian Heart J; 2019; 71(4):303-308. PubMed ID: 31779857
[TBL] [Abstract][Full Text] [Related]
6. The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Çınar T; Tanık VO; Aruğaslan E; Karabağ Y; Çağdaş M; Rencüzoğulları İ; Keskin M
Cardiovasc Interv Ther; 2019 Jul; 34(3):207-215. PubMed ID: 30191494
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of newly defined CHA2DS2-VASc-HSF score for severity of coronary artery disease in ST segment elevation myocardial infarction.
Uysal OK; Turkoglu C; Duran M; Kaya MG; Sahin DY; Gur M; Cayli M
Kardiol Pol; 2016; 74(9):954-60. PubMed ID: 27112941
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of CHA2DS2-VASc Score in Patients with Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction.
Dönmez E; Özcan S; İnce O; Şahin İ; Okuyan E
Turk Kardiyol Dern Ars; 2023 Mar; 51(2):97-103. PubMed ID: 36916809
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of CHA2DS2-VASC Score for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Kurtul A; Yarlioglues M; Duran M
Am J Cardiol; 2017 Mar; 119(6):819-825. PubMed ID: 28040187
[TBL] [Abstract][Full Text] [Related]
10. CHA
Bozbay M; Uyarel H; Cicek G; Oz A; Keskin M; Murat A; Yildirim E; Karaca G; Ergelen M; Eren M
Clin Appl Thromb Hemost; 2017 Mar; 23(2):132-138. PubMed ID: 27170782
[TBL] [Abstract][Full Text] [Related]
11. Association of Serum Osmolarity With Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction.
Yildiz I; Yildiz PO; Rencuzogullari I; Karabag Y; Cagdas M; Burak C; Gurevin MS
Angiology; 2019 Aug; 70(7):627-632. PubMed ID: 30712366
[TBL] [Abstract][Full Text] [Related]
12. CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction.
Ashoori A; Pourhosseini H; Ghodsi S; Salarifar M; Nematipour E; Alidoosti M; Haji-Zeinali AM; Nozari Y; Amirzadegan A; Aghajani H; Jalali A; Hosseini Z; Jenab Y; Geraiely B; Omidi N
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717292
[TBL] [Abstract][Full Text] [Related]
13. The Predictive Value of CHA2DS2-VASc Score on Residual Syntax Score in Patients With ST Segment Elevation Myocardial Infarction.
Kalkan AK; Kahraman S; Avci Y; Bulut U; Gulmez R; Turkyilmaz AB; Erturk M
Arq Bras Cardiol; 2022 Sep; 119(3):393-399. PubMed ID: 35830076
[TBL] [Abstract][Full Text] [Related]
14. CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention.
Ipek G; Onuk T; Karatas MB; Gungor B; Osken A; Keskin M; Oz A; Tanik O; Hayiroglu MI; Yaka HY; Ozturk R; Bolca O
Angiology; 2016 Oct; 67(9):840-5. PubMed ID: 26685178
[TBL] [Abstract][Full Text] [Related]
15. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
[TBL] [Abstract][Full Text] [Related]
16. CHA2DS2-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention.
Huang X; Zheng W; Zhao XD; Nie SP
Medicine (Baltimore); 2021 May; 100(21):e26162. PubMed ID: 34032776
[TBL] [Abstract][Full Text] [Related]
17. CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions.
Baydar O; Kilic A
Kidney Dis (Basel); 2019 Oct; 5(4):266-271. PubMed ID: 31768384
[TBL] [Abstract][Full Text] [Related]
18. Value of CHA2DS2-VASc Score for Prediction and Ruling Out of Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention.
Açikgöz SK; Açikgöz E; Çiçek G
Angiology; 2020 May; 71(5):411-416. PubMed ID: 32030991
[TBL] [Abstract][Full Text] [Related]
19. Association between copeptin and contrast-induced nephropathy in patients with ST-elevation myocardial infarction.
Yildirim E; Cabbar AT
Rev Port Cardiol (Engl Ed); 2019 Dec; 38(12):873-879. PubMed ID: 32165078
[TBL] [Abstract][Full Text] [Related]
20. Inter-arm blood pressure difference is associated with contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.
Simsek Z; Zehir R; Kalkan S; Ceneli D; Alizade E; Bayam E; Candan Ö
Clin Exp Hypertens; 2022 Apr; 44(3):258-262. PubMed ID: 35060428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
